Physician profile
Amy Strowbridge
NPI 1366534653
$741.04
in general payments reported to CMS, 2019-2025
18 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.03 · 2020: $101 · 2021: $65.24 · 2022: $13.01 · 2023: $129 · 2024: $128 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $495.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $125.03 | 2021-2025 | Monjuvi, Jakafi |
| Astrazeneca Pharmaceuticals LP | $72.44 | 2024-2025 | Imfinzi |
| Novartis Pharmaceuticals Corporation | $68.41 | 2022-2023 | |
| Janssen Biotech, INC. | $54.77 | 2020-2023 | Darzalex, Tecvayli |
| Merck Sharp & Dohme LLC | $51.54 | 2024-2025 | Keytruda, Welireg |
| Amgen INC. | $51.40 | 2019 | |
| Genentech USA, INC. | $46.76 | 2024-2025 | Polivy, Tecentriq |
| Daiichi Sankyo INC. | $43.21 | 2021-2025 | Enhertu |
| Pharmacosmos Therapeutics INC. | $39.70 | 2025 | Monoferric |
| Jazz Pharmaceuticals INC. | $35.97 | 2020 | |
| Tersera Therapeutics LLC | $35.30 | 2025 | Zoladex |
| Lilly USA, LLC | $27.27 | 2023 | Verzenio, Jaypirca |
| Takeda Pharmaceuticals U.S.A., INC. | $17.33 | 2025 | Fruzaqla |
| Advanced Accelerator Applications | $16.79 | 2020 | |
| Pfizer INC. | $15.87 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $15.63 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $11.85 | 2021 | |
| Seagen INC. | $11.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Strowbridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.